Key result
Contemporary treatment strategies for acute heart failure vary greatly between the USA and Japan, with notable differences in the use and dosing of diuretics, natriuretic peptides, and tolvaptan.
This review highlights significant regional differences in the pharmacological management of acute heart failure between the USA and Japan, providing a framework for evaluating practice patterns.
Highlights wide regional variation in acute HF care; leaves open optimal strategies pending comparative outcome trials.
Globally, acute heart failure (AHF) remains an ongoing public health issue with its prevalence and mortality increasing in the east and the west. Effective treatment strategies to stabilize AHF are important to alleviate clinical symptoms and to improve clinical outcomes. However, despite the progress in the management of stable and chronic heart failure, no single agent has been proven to play a definitive role in the management of AHF. As a consequence, contemporary treatment strategies for patients with AHF vary greatly by region. This manuscript reviews the medical treatment options for AHF, with an emphasis on the differences between the treatment strategies in the USA and Japan. This information would provide a framework for clinicians to evaluate and manage patients with AHF and highlight the remaining questions to improve clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2018) conducted a review in Acute heart failure. Acute heart failure medical management was evaluated. Contemporary treatment strategies for acute heart failure vary greatly between the USA and Japan, with notable differences in the use and dosing of diuretics, natriuretic peptides, and tolvaptan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: